Newswise — Washington, DC—Women with a history of gestational diabetes face a heightened risk of developing Type 2 diabetes for years after giving birth, but intensive lifestyle intervention or a medication regimen can have a protective effect in this population, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism.
Gestational diabetes is a form of diabetes that occurs during pregnancy, typically in the second trimester. The condition causes glucose levels in the bloodstream to rise above normal levels. Gestational diabetes occurs during as many as 9.2 percent of pregnant women, according to the U.S. Centers for Disease Control and Prevention.
“Our long-term follow-up study found the elevated risk of developing Type 2 diabetes persisted for years in women who had been diagnosed with gestational diabetes, and this long-term risk can be reduced with either intensive lifestyle intervention or the medication metformin,” said one of the study’s authors, Vanita Aroda, MD, of the MedStar Health Research Institute in Hyattsville, MD.
The Diabetes Prevention Program Outcomes Study (DPPOS) analyzed long-term metabolic health in 288 women who had a previous diagnosis of gestational diabetes and 1,226 mothers who did not have a history of the condition. The women all participated in the initial Diabetes Prevention Program study, a randomized clinical trial where they were assigned to intensive lifestyle intervention, the diabetes medication metformin or a placebo. The intensive lifestyle intervention was aimed at reducing body weight by 7 percent and participating in moderate cardio exercise for 150 minutes a week.
During the DPPOS, the women continued to have their blood glucose levels measured twice a year for six years. The study looked at long-term health outcomes in Diabetes Prevention Program participants for about a decade after the women first enrolled in the study.
Women with a history of gestational diabetes who were assigned to take the medication metformin or undergo the intensive lifestyle intervention were less likely to develop Type 2 diabetes than women who received the placebo. When they were assigned the placebo, women who had a history of gestational diabetes had a 48 percent higher risk of developing diabetes compared to women who were never diagnosed with the condition.
Women who had been diagnosed with gestational diabetes and underwent intensive lifestyle intervention had a 35.2 percent reduction in their risk of developing Type 2 diabetes. The risk was reduced by 40.4 percent among women with a history of the condition who were assigned to take metformin.
“Medical and lifestyle interventions were remarkably effective at slowing the progression of Type 2 diabetes in this at-risk population in both the short and long term,” Aroda said.
Other authors of the study for the Diabetes Prevention Research Group include: Costas Christophi and Sharon Edelstein of the George Washington University Biostatistics Center in Rockville, MD; Ping Zhang and Xiaohui Zhuo of the Centers for Disease Control and Prevention in Atlanta, GA; William H. Herman of the University of Michigan in Ann Arbor, MI; Elizabeth Barrett-Connor of the University of California-San Diego in La Jolla, CA; Linda M. Delahanty of Massachusetts General Hospital and Harvard Medical School in Boston, MA; Maria G. Montez of the University of Texas Health Science Center in San Antonio, TX; Ronald T. Ackermann of the Northwestern University Feinberg School of Medicine in Chicago, IL; William C. Knowler of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in Phoenix, AZ; and Robert E. Ratner of the MedStar Health Research Institute.
The study, “The Effect of Lifestyle Intervention and Metformin on Preventing or Delaying Diabetes among Women with and without Gestational Diabetes: The Diabetes Prevention Program Outcomes Study 10-Year Follow Up,” was published online, ahead of print.
The Diabetes Prevention Program Outcomes Study was funded under National Institutes of Health grant U01DK048489 by the NIDDK; National Institute on Aging; National Cancer Institute; National Heart, Lung, and Blood Institute; National Eye Institute; National Center on Minority Health and Health Disparities; and the Office of the NIH Director; Eunice Kennedy Shriver National Institute of Child Health and Human Development; Office of Research on Women’s Health; and Office of Dietary Supplements, all part of the NIH, as well as the Indian Health Service, Centers for Disease Control and Prevention and American Diabetes Association. Funding in the form of supplies was provided by Merck Sante, Merck KGaA and LifeScan.
# # #
Founded in 1916, the Endocrine Society is the world’s oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, the Endocrine Society’s membership consists of over 18,000 scientists, physicians, educators, nurses and students in 122 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Washington, DC. To learn more about the Society and the field of endocrinology, visit our site at www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.